CTOs on the Move

SHINE Technologies

www.shinefusion.com

 
Based in Janesville, Wisconsin, SHINE deploys its safe, cost-effective and environmentally friendly fusion technology in a stepwise approach. Its systems are used to inspect industrial components in aerospace, defense, energy and other sectors. SHINE`s proprietary medical isotope production processes create non-carrier-added lutetium-177 and are expected to create molybdenum-99. In the future, SHINE plans to scale its fusion technology to help solve one of energy`s toughest hurdles by recycling nuclear waste. Through a purpose-driven and phased approach, SHINE aims to generate fusion power to deliver clean, abundant energy that could transform life on Earth
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Eli Moll
Chief Operating Officer Profile

Funding

SHINE Technologies raised $30M on 11/27/2018
SHINE Technologies raised $18M on 07/01/2019
SHINE Technologies raised $50M on 10/07/2019
SHINE Technologies raised $150M on 06/28/2021

Similar Companies

Champions Oncology

Champions Oncology is a company that develops technology solutions and services for personalizing the development and use of oncology drugs. Their technology-enabled research platforms empower biopharma to create a comprehensive understanding of tumor ...

Nova-Tech Engineering Inc

Nova-Tech Engineering Inc is a Willmar, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pharmacompany

Pharmacompany is a Boston, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Polymer Science,

Custom coater, converter and packager for the medical, electronics, automotive and general industrial markets.

Karyopharm

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm`s SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm`s lead compound, XPOVIO™ (selinexor), received accelerated approval from the FDA in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. A Marketing Authorization Application for selinexor is also currently under review by the European Medicines Agency. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development.